Cannara Biotech Inc (OTCPK:LOVFF)
$ 1.2135 +0.064 (+5.52%) Market Cap: 123.31 Mil Enterprise Value: 131.98 Mil PE Ratio: 16.62 PB Ratio: 1.44 GF Score: 83/100

Q1 2026 Cannara Biotech Inc Earnings Call Transcript

Jan 26, 2026 / 04:00PM GMT
Release Date Price: $1.39 (-3.88%)

Key Points

Positve
  • Cannara Biotech Inc (LOVFF) reported its 19th consecutive quarter of positive adjusted EBITDA and 13th quarter of positive operating cash flow, demonstrating consistent profitability.
  • The company achieved a record high 45% gross margin, up from 39% last year, reflecting increased production capacity and efficiency improvements.
  • Cannara Biotech Inc (LOVFF) captured over 29.7% of Quebec's vape category retail sales, establishing a strong market presence.
  • The company plans a $30 million CapEx over the next three years to double its production capacity, indicating a clear growth strategy.
  • Cannara Biotech Inc (LOVFF) maintained a strong financial position with $16.5 million in cash and $53.5 million in working capital, supporting its expansion plans.
Negative
  • Net income was positive but down year over year due to non-cash adjustments related to fair value changes of inventory and share-based compensation.
  • The BC strike resulted in a five-week halt in sales, although the company managed to maintain market share post-strike.
  • The national retail environment softened, with total Canadian retail sales down approximately 4% quarter over quarter.
  • Cannara Biotech Inc (LOVFF) faces challenges in the edibles market due to regulatory constraints and increased competition.
  • The company anticipates potential input cost increases once Valley Field no longer benefits from current electricity rates.
Scott Carroll
Cannara Biotech Inc - Vice President - Commercial Strategy and Marketing

Morning everyone and welcome to Cannara Biotech's fiscal Q1 2026 financial results for the three months ending November 30th, 2025. My name is Scott Carroll, and I will be your moderator today. As a reminder, this presentation is being recorded. (Operator Instructions)

Before we begin, please refer to slide 2 and 3 of our earnings presentation. All information presented today is subject to our general disclaimers on financial measures and forward-looking statements, which are available to be read in detail at sedarplus.ca.

I will now turn the call over to Cannara Biotech's CFO, Nicholas Sosiak, who will be leading today's presentation. He'll be joined by our founder and CEO, Zohar Krivorot, for the live Q&A session following this presentation.

Nicholas Sosiak
Cannara Biotech Inc - Chief Financial Officer

Thank you, Scott. Good morning, everyone, and thank you for joining Kar's earning presentation for the fiscal quarter 2026 ended November 30th, 2025

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot